When groups work together to it is manipulation. Trails of phone calls, emails, etc. give SEC all they need to prosecute. But when they just have a signal- such as a hit piece by an alleged reporter- they eliminate all this evidence. So bottom line is he is just the signal to take action, then they move in like vultures and take a stock in any direction they want. Ever wonder why they do this to stocks with low floats and market caps of a few hundred million or less? Because they have enough resources to move them in any direction they want. Good luck Gizmo.
I have come to realize Feuerstein is just a signal to certain groups to manipulate together. Individually they can do nothing... If they coordinate this together sec has all sorts of ways to connect the dots. He is just enabling the attacks while limiting what the sec can do.
Samsa- The funny thing is these guys claim to have a large core position... The thing they will soon find is they have given IPCI the rep as a pump and dump and they will never be able to get out of that core position as the price never stays up.
Samsa- The reason I posted this is because it shows how IPCI plans to fund operations in the short term. Bottom line is they will use ATM until they have better options.
Jonathan Aschoff, Brean Capital (4/15/16)
"We estimate that the freedom to forego Phase 3 testing [for Rexista] has saved Intellipharmaceutics International Inc. at least $20M from the cost of development, as well as about 18-24 months. The company also filed an NDA user fee waiver request with the FDA, which would save $1.2M. . .the result of this request is expected before the company files the NDA for Rexista."
Jason Kolbert, Maxim Group (4/15/16)
"As additional elements of the abuse technology are validated with third-party clinical studies we expect to see Intellipharmaceutics International Inc.'s Rexista lead to a partnership opportunity that could trigger both capital and set the stage for the company to raise capital at a higher valuation. . .in the interim period we expect the judicious use of the ATM facility to fund the company as Rexista marches forward. . .we expect the stock to be driven by progress with Rexista and ultimately PODRAS."
If you have not, make sure you contact the company and let them know you expect them to file on time.
Day 1 would be dose 1, so day 105 or 106 would be sixth dose. But I do understand what you are pointing out.
For a journalist to say something outside of their field of expertise without citing a reference is uncredited. The Street is right up there with the National enquirer. If you want to see shareholders that have been screwed by their choice, take a look at TST long term chart... Then review Jimmy boys compensation for all those years. I vote Jimmy Cramer for worst ceo.
Gophr- Look at the KM plots, but here is a rough idea:
Investigator Plot- Day 105(roughly day of 6th/final dose)- 80% had not progressed on Aldox
Central Lab Plot- Day 105(roughly day of 6th/final dose)- 60% had not progressed on Aldox
Lets hope the Investigator's plot is more representative of this study!
I absolutely agree! This is an excellent way to get the word out and keep investors and potential investors abreast of what is going on. Keep up the good work IPCI.
Other reason is PFS as acceptable primary endpoint in 2nd line trials is easily sold to FDA.
So what would be a better way to raise cash right now? I would say take out a loan. A public offering does not make sense now either. So I vote for a loan until after NDA submission.
The thing people need to keep in mind is at least 50% of the patients need to respond to Aldox. The factor that influences median PFS(the point on the KM curve where 50% have progressed) the most is the % of the population that respond to the drug. Lots of people mistakenly think median PFS is an average of PFS data... It is not... It is the point where 50% of the population has progressed. All that being said, if at least 60% of the Aldox patients respond to the drug, the results will be very good. If less than 50% of the patients respond to Aldox, dosing until progression will not help median PFS number.
Nice interview and shows direction of company. Next big catalyst will be Rexista NDA filing. After filing it sounds like they will entertain partner offers but nothing before. Sounds like Regabatin will indeed be partnered prior to clinical trials as well.